Logo image of VIRI

VIRIOS THERAPEUTICS INC (VIRI) Stock Fundamental Analysis

NASDAQ:VIRI - Nasdaq - US92829J1043 - Common Stock - Currency: USD

0.155  +0.02 (+12.4%)

After market: 0.1452 -0.01 (-6.32%)

Fundamental Rating

2

Taking everything into account, VIRI scores 2 out of 10 in our fundamental rating. VIRI was compared to 559 industry peers in the Biotechnology industry. While VIRI seems to be doing ok healthwise, there are quite some concerns on its profitability. VIRI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VIRI has reported negative net income.
In the past year VIRI has reported a negative cash flow from operations.
In the past 5 years VIRI always reported negative net income.
VIRI had a negative operating cash flow in each of the past 5 years.
VIRI Yearly Net Income VS EBIT VS OCF VS FCFVIRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

VIRI has a Return On Assets of -145.66%. This is amonst the worse of the industry: VIRI underperforms 85.31% of its industry peers.
VIRI has a Return On Equity of -168.89%. This is in the lower half of the industry: VIRI underperforms 66.02% of its industry peers.
Industry RankSector Rank
ROA -145.66%
ROE -168.89%
ROIC N/A
ROA(3y)-124.88%
ROA(5y)-235.88%
ROE(3y)-138.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VIRI Yearly ROA, ROE, ROICVIRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VIRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIRI Yearly Profit, Operating, Gross MarginsVIRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, VIRI has more shares outstanding
The number of shares outstanding for VIRI has been increased compared to 5 years ago.
There is no outstanding debt for VIRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIRI Yearly Shares OutstandingVIRI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 5M 10M 15M
VIRI Yearly Total Debt VS Total AssetsVIRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -28.27, we must say that VIRI is in the distress zone and has some risk of bankruptcy.
VIRI has a Altman-Z score of -28.27. This is amonst the worse of the industry: VIRI underperforms 89.56% of its industry peers.
VIRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.27
ROIC/WACCN/A
WACCN/A
VIRI Yearly LT Debt VS Equity VS FCFVIRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 7.27 indicates that VIRI has no problem at all paying its short term obligations.
VIRI has a Current ratio of 7.27. This is in the better half of the industry: VIRI outperforms 68.85% of its industry peers.
VIRI has a Quick Ratio of 7.27. This indicates that VIRI is financially healthy and has no problem in meeting its short term obligations.
VIRI's Quick ratio of 7.27 is fine compared to the rest of the industry. VIRI outperforms 69.03% of its industry peers.
Industry RankSector Rank
Current Ratio 7.27
Quick Ratio 7.27
VIRI Yearly Current Assets VS Current LiabilitesVIRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

VIRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.36%, which is quite impressive.
EPS 1Y (TTM)56.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VIRI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.70% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.86%
EPS Next 2Y18.28%
EPS Next 3Y6.76%
EPS Next 5Y12.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIRI Yearly Revenue VS EstimatesVIRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 20M 40M 60M
VIRI Yearly EPS VS EstimatesVIRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VIRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIRI Price Earnings VS Forward Price EarningsVIRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIRI Per share dataVIRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.28%
EPS Next 3Y6.76%

More info and screens

0

5. Dividend

5.1 Amount

VIRI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIOS THERAPEUTICS INC

NASDAQ:VIRI (10/8/2024, 8:00:02 PM)

After market: 0.1452 -0.01 (-6.32%)

0.155

+0.02 (+12.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)11-11 2024-11-11/bmo
Inst Owners99.68%
Inst Owner Change-31.7%
Ins Owners83.34%
Ins Owner Change0%
Market Cap172.05K
Analysts80
Price Target1.43 (822.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.49%
Min EPS beat(2)-71.57%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)5.94%
Min EPS beat(4)-71.57%
Max EPS beat(4)38.08%
EPS beat(8)6
Avg EPS beat(8)18.36%
EPS beat(12)10
Avg EPS beat(12)18.83%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.33%
EPS NY rev (1m)0%
EPS NY rev (3m)18.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.05
P/tB 0.05
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-3.77
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS0
BVpS2.83
TBVpS2.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -145.66%
ROE -168.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-124.88%
ROA(5y)-235.88%
ROE(3y)-138.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.27
Quick Ratio 7.27
Altman-Z -28.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y19.86%
EPS Next 2Y18.28%
EPS Next 3Y6.76%
EPS Next 5Y12.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.44%
OCF growth 3YN/A
OCF growth 5YN/A